natgillin/translations-raw huggingface dataset:
with chronic lymphocytic leukaemia (a cancer of a type of white blood cell) and frequent bacterial infections after preventive treatment with antibiotics has failed;
kronično limfocitno levkemijo (rakom vrste belih krvnih celic) in pogostimi bakterijskimi okužbami po neuspelem preventivnem zdravljenju z antibiotiki;
With chronic use in the RE-LY study, NSAIDs increased the risk of bleeding by approximately 50 % on both dabigatran etexilate and warfarin.
Pri kronični uporabi NSAR v raziskavi RE-LY se je tveganje krvavitev ob dajanju dabigatran eteksilata in varfarina povečalo za 50 %.
With chronic use in the RE-LY study, NSAIDs increased the risk of bleeding by approximately 50% on both dabigatran etexilate and warfarin.
Pri kronični uporabi NSAR v raziskavi RE-LY se je tveganje krvavitev ob dajanju dabigatran eteksilata in varfarina povečalo za 50 %.
With chronic use NSAIDs increased the risk of bleeding by approximately 50 % on both dabigatran etexilate and warfarin.
Pri kronični uporabi NSAR se je tveganje krvavitev ob dajanju dabigatran eteksilata in varfarina povečalo za 50 %.
With cirrhosis**
S cirozo
with clarithromycin or
ali s terfenadinom ni
with co-administration of Kaletra
izpostavljenosti rifabutinu je
With concomitant use of MTX, treatment with 50 mg golimumab subcutaneously every 4 weeks resulted in a mean ( standard deviation) steady-state trough serum concentration of approximately 0.6  0.4 g/mL in RA patients with active RA despite MTX therapy, and approximately 0.5  0.4 g/mL in patients with active PsA and approximately 0.8  0.4 g/mL in patients with AS.
Pri sočasni uporabi metotreksata je zdravljenje s 50 mg golimumaba subkutano na vsake 4 tedne vodilo do srednje vrednosti (± standardna deviacija) najnižje serumske koncentracije v stanju dinamičnega ravnovesja približno 0,6 ± 0,4 g/ml pri bolnikih z aktivnim revmatoidnim artritisom kljub zdravljenju z metotreksatom, približno 0,5 ± 0,4 g/ml pri bolnikih z aktivnim psoriatičnim artritisom in približno 0,8 ± 0,4 g/ml pri bolnikih z ankilozirajočim spondilitisom.
With continued long- term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure- free for at least 1 year.
Z nadaljevanjem dolgotrajnega zdravljenja je bilo 11,4 % bolnikov brez napada vsaj 6 mesecev, 7,2 % pa jih je bilo brez napada vsaj 1 leto.
With continued long-term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure-free for at least 1 year.
Z nadaljevanjem dolgotrajnega zdravljenja je bilo 11,4 % bolnikov brez napada vsaj 6 mesecev, 7,2 % pa jih je bilo brez napada vsaj 1 leto.
With continued long-term treatment, 8.6 % of the patients were seizure- free for at least 6 months and 7.8 % were seizure-free for at least 1 year.
Pri nadaljnjem dolgotrajnem zdravljenju je bilo 8,6 % bolnikov brez napadov najmanj 6 mesecev in 7,8 % bolnikov najmanj 1 leto.
With continued long-term treatment, 8.6% of the patients were seizure-free for at least
Pri nadaljnjem dolgotrajnem zdravljenju je bilo 8,6 % bolnikov brez napadov najmanj
with continuous infusion (in
nadaljevati s kontinuirano infuzijo
with continuous infusion (in
nadaljujte s kontinuirano infuzijo
With current data it is not known if infliximab treatment influences the risk for developing dysplasia or colon cancer (see section 4.8).
Glede na dosedanje podatke ni znano, ali zdravljenje z infliksimabom vpliva na tveganje za nastanek displazije ali karcinoma kolona (glejte poglavje 4.8).
with CYP3A4- inducing agents (see section 4.5)
CYP3A4 (glejte poglavje 4.5)
With dabrafenib monotherapy, approximately 70% of events occurred within the first 12 weeks of treatment with a median time to onset of 8 weeks.
Pri jemanju dabrafeniba v monoterapiji se je približno 70 % dogodkov pojavilo v prvih 12 tednih zdravljenja; mediani čas do nastanka je bil 8 tednov.
With dogs weighing 15 kg or more, apply 8 drops to the ear once a day.
Psom s telesno maso 15 kg in več dajemo 8 kapljic zdravila v sluhovod enkrat dnevno.
With dogs weighing 2-15 kg, apply 4 drops to the ear once a day.
Psom s telesno maso od 2do 15 kg dajemo 4 kapljice zdravila v sluhovod enkrat dnevno.
With doses of 15 mg/kg and higher, intermittent mild treatment-associated diarrhoea was noted.
Ob odmerkih 15 mg/kg in več so ugotovili intermitentno, blago z zdravilom povezano diarejo.
With dry hands press gently to release the tablet on your hand.
S suhimi rokami nežno iztisnite tableto na dlan.
With dry hands, press gently to release the tablet on your hand.
S suhimi rokami nežno iztisnite tableto na dlan.
With dry hands, remove capsule from the blister.
Kapsulo vzemite iz pretisnega omota s suhimi rokami.
With each new pen, check the flow
Vedno ko uporabite nov injekcijski peresnik, preverite pretok
With each step, you will add one 200 microgram tablet to your morning dose and another
Z vsakim korakom boste dodali eno 200-mikrogramsko tableto jutranjemu odmerku in še eno
with efavirenz 600 mg daily.
600 mg na dan so opazili
With efavirenz, an increase of
Pri sočasni uporabi z efavirenzem
with emergent NS5A RAVs***
s pojavom RAV NS5A
with etravirine.
očasno z etravirinom.
with EVOTAZ.
lahko povečajo.
With experience, you will find the angle that is most comfortable for the child.
Z izkušnjami boste našli kot, ki je za otroka najustreznejši.
With experience, you will find the angle that is most comfortable for you or the child.
Z izkušnjami boste našli kot, ki je za vas ali otroka najustreznejši.
With experience, you will find the angle that is most comfortable for you.
Z izkušnjami boste našli kot, ki je za vas najustreznejši.
with extensive PI
obsežno
with famotidine.
očasno s famotidinom.
with food).
didanozin:
with food.
skupaj s hrano.
With Grade 3 or 4 left ventricular cardiac dysfunction or if LVEF does not recover trametinib should be permanently discontinued (see section 4.4).
V primeru disfunkcije levega prekata 3. ali 4. stopnje, ali če se LVEF ne popravi, je treba zdravljenje s trametinibom trajno končati (glejte poglavje 4.4).
With hepatic enzyme-inducing substances, a barrier method should be used during the time of concomitant medicinal product administration and for 28 days after their discontinuation.
Med sočasno uporabo zdravil, ki vsebujejo zdravilne učinkovine, ki inducirajo jetrne encime, in še 28 dni po ukinitvi teh zdravil mora ženska uporabljati pregradno metodo kontracepcije.
With hepatitis B vaccination at birth
s cepljenjem proti hepatitisu B ob rojstvu
with HIV infection;
bolnikih z okužbo z virusom HIV;
With hydrochlorothiazide, onset of diuresis occurs in 2 hours, and peak effect occurs at about 4 hours, while the action persists for approximately 6-12 hours.
Hidroklorotiazid sproži diurezo v 2°urah, doseže največji učinek približno po 4 urah, njegovo delovanje pa traja približno 6 do 12°ur.
with hypersensitivity to parathyroid hormone or to any of the excipients (see section 6.1)
preobčutljivostjo za obščitnični hormon ali katerokoli pomožno snov (glejte poglavje 6.1)
with hypersensitivity to the active substance or to any of the excipients
preobčutljivostjo za zdravilno učinkovino ali katerokoli pomožno snov,
with increased monitoring for
je to potrebno izvesti v enoti za
with increasing age (beyond about 35 years);
z naraščanjem starosti (nad približno 35 let);
with increasing pH related to the
višjem pH-ju zaradi antacidnega
With increasing renal impairment, from mild (CLcr 50 to < 80 ml/min) to moderate (CLcr 30 to < 50 ml/min) to severe renal impairment (CLcr < 30 ml/min), the fraction of regadenoson excreted unchanged in urine and the renal clearance decreased, resulting in increased elimination half- lives and AUC values compared to healthy subjects (CLcr ml/min).
Z večanjem okvare ledvic, od blage (očistek kreatinina 50 to < 80 ml/min) do zmerne (očistek kreatinina 30 do < 50 ml/min) in hude okvare ledvic (očistek kreatinina < 30 ml/min), se je frakcija regadenozona nespremenjena izločala v urinu in ledvični očistek se je manjšal, kar je povzročilo podaljšanje razpolovnih časov izločanja in vrednosti AUC v primerjavi z zdravimi osebami (očistek kreatinina ≥ 80 ml/min).
with indinavir/ritonavir.
premljanje terapevtskih in
With inhibition of the decarboxylase by a DDC inhibitor, catechol-O-methyltransferase (COMT) becomes the major peripheral metabolic pathway catalyzing the conversion of levodopa to 3-O- methyldopa (3-OMD), a potentially harmful metabolite of levodopa.
Po zavrtju dekarboksilaze z zaviralcem DDK postane katehol-O-metiltransferaza (COMT) glavna periferna pot presnove, ki katalizira pretvorbo levodope v 3-O-metildopo (3-OMD), potencialno škodljiv presnovek levodope.
With inhibitor
z zaviralcem
with insulin
Neželeni učinek
with insulin
pogosti
with insulin
z insulinom
with insulin
z inzulinom
with INTELENCE in the
zdravilom INTELENCE in
with INTELENCE may result in higher plasma
lahko vodi do večjih plazemskih koncentracij
with intravenous midazolam.
Pri sočasni
with Kaletra (see section 4.4).
Kaletra (glejte poglavje 4.4)
with ketoacidosis or
ketoacidozo ali komo,
with ketoconazole.
očasno s ketokonazolom.
with large ovaries or sacs of fluids within the ovaries (ovarian cysts) of unknown origin.
povečanjem jajčnika ali vrečkami tekočine znotraj jajčnikov (ciste jajčnika) neznanega izvora;
with limited treatment options2,3
bolnikih z omejenimi
With long-term exposure (at least 24 weeks), 89.4 % gained ≥ 7 %, 55.3
Pri dolgoročni izpostavljenosti (najmanj 24 tednov) jih je približno 89,4 % pridobilo
With long-term exposure (at least 24 weeks), 89.4 % gained ≥ 7 %, 55.3
Pri dolgotrajni izpostavljenosti (najmanj 24 tednov) je 89,4 % pridobilo ≥ 7 %, 55,3
With longer exposure, frequency of adverse events increased; however no new safety findings emerged.
Pri daljšem trajanju izpostavljenosti se je pogostnost neželenih učinkov povečala, pri tem pa niso ugotavljali nobenih novih dejstev glede varnosti zdravila.
with lopinavir/ritonavir.
fenobarbitalom je treba predvideti
with low dose ritonavir
majhnim odmerkom ritonavirja
with low dose ritonavir
majhnim odmerkom ritonavirja (600/100 mg dvakrat na dan)
with low dose ritonavir (600/100 mg twice daily) is used in
(600/100 mg dvakrat na dan)
with low dose ritonavir and
odmerkom ritonavirja ni
with low dose ritonavir in doses
odmerkom ritonavirja (razen
with low dose ritonavir is required,
pravastatina in zdravila PREZISTA z majhnim odmerkom ritonavirja, je
with low dose ritonavir resulting in
odmerkom ritonavirja zvišajo, kar
with low dose ritonavir, the
majhnim odmerkom ritonavirja, se
with low dose ritonavir.
treba zmanjšati odmerek teh zdravil.
With MAO inhibitors there have been reports of medicinal product interactions with the concomitant use of sympathomimetic medicinal products.
Obstajajo poročila o medsebojnih interakcijah zdravil pri sočasni uporabi inhibitorjev MAO in simpatikomimetičnh zdravil.
With MAO inhibitors, there have been reports of drug interactions with the concomitant use of sympathomimetic medicinal products.
Ob sočasni uporabi inhibitorjev MAO in simpatikomimetičnih zdravil so poročali o medsebojnih interakcijah.
With MAO-inhibitors there have been reports of drug interactions with concomitant use of sympathomimetic medicinal products.
O interakciji med zdravili so poročali tudi pri sočasni uporabi zaviralcev MAO in simpatomimetikov.
with maraviroc.
očasno z maravirokom.
with medicinal products that
zdravili, ki spremenijo želodčni pH,
with medicines containing pimozide (used to treat psychiatric illnesses), terfenadine and astemizole (used for hay fever and other allergic conditions), cisapride (used for treating digestive problems).
skupaj z zdravili, ki vsebujejo pimozid (ki se uporablja za zdravljenje psihiatričnih bolezni), terfenadin ali astemizol (ki se uporabljata za zdravljenje senenega nahoda in drugih alergij) ali cisaprid (ki se uporablja za zdravljenje prebavnih težav).
with metformin
Srčne bolezni
with metformin
z metfor- minom
with metformin
z metforminom
with metformin
z metforminom in sulfonil- sečnino
with metformin and sulpho- nylurea
Benigne, maligne in neopredeljene neoplazme
with metformin and sulpho- nylurea
rčno popuščanje3
with metformin and sulpho- nylurea
z metfor- minom in sulfonil- sečnino
with metformin and sulpho- nylurea
z metforminom in sulfonil- sečnino
With metformin and with pioglitazone, the 100 mg daily dose was more effective than the 50 mg daily dose, with a reduction in HbA1c levels of between 0.8 and 1.0 percentage points.
Pri njegovi uporabi z metforminom in pioglitazonom je bil 100-miligramski dnevni odmerek učinkovitejši od 50- miligramskega, pri čemer se je koncentracija HbA1c znižala za 0,8 do 1,0 odstotne točke.
with methadone.
očasno z metadonom.
with MR4.5
24%, p<0,0013
with multiple myeloma (another cancer of a type of white blood cell) and frequent bacterial infections and in whom vaccination against ‘pneumococcal’ bacteria has failed; who have had haematopoietic (blood) stem cell transplantation (when the patient receives stem cells from a matched donor to help restore the bone marrow).
z multiplim mielomom (drugo obliko raka vrste belih krvnih celic) in pogostimi bakterijskimi okužbami po neuspelem cepljenju proti pnevmokoknim bakterijam; s presaditvijo hematopoetskih (krvotvornih) matičnih celic (kadar bolnik prejme matične celice darovalca, ki se ujemajo z njegovimi in pomagajo obnoviti kostni mozeg);
With needle pointed up, push Dose Knob in until it stops and 0
Z iglo usmerjeno navzgor, pritisnite gumb za odmerjanje so konca,
with needle safety
uporaba
With no associated boosted PI (out of the
Brez okrepljenega PI (ni indicirano za
With non- dopaminergic receptors, rotigotine showed antagonism at alpha2B and agonism at 5HT1A receptors, but no activity on the 5HT2B receptor.
Pri nedopaminergičnih receptorjih ima rotigotin antagonistično delovanje na receptorje α 2B in agonistično delovanje na receptorje 5HT1A, na 5HT2B receptorje pa ne deluje.
With normal immunoglobulins adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Z normalnimi imunoglobulini se priložnostno lahko pojavijo neželeni učinki, kot so mrzlica, glavobol, zvišana telesna temperatura, bruhanje, alergijske reakcije, slabost, bolečine v sklepih, nizek krvni tlak in zmerna bolečina v križu.
with omeprazole.
sočasno z omeprazolom.
With one hand grasp the powder-side of the
Z eno roko primite set Mix2Vial na tisti strani, kjer je viala s praškom.
With one hand grasp the product-side of the Mix2Vial set and with the other hand grasp the solvent-side and unscrew counterclockwise the set carefully into two pieces.
Z eno roko primite komplet Mix2Vial na strani kjer je zdravilo, z drugo roko pa na strani kjer je vehikel in razstavite komplet na dva dela z odvijanjem v nasprotni smeri urnih kazalcev.
With one hand hold your penis.
Penis držite z eno roko.
With one hand, gently grasp the cleaned areas of skin and hold firmly
Z eno roko obzirno primite očiščeni predel kože in ga trdno držite.
With one hand, gently pinch the cleaned area of skin and hold it firmly.
Z eno roko rahlo stisnite očiščeni predel kože in ga trdno držite.
With one hand, hold pipette in an upright position away from your face and with the other hand, snap tip open by bending it and folding it back on itself.
Z eno roko držite merilno kapalko v pokončnem položaju stran od obraza, z drugo roko pa odtrgajte konico, tako da jo prepognete in zavijete nazaj.
With one hand, hold pipette in an upright position away from your face and with the other hand, snap tip open by bending it and folding it back on itself.
Z eno roko držite merilno kapalko v pokončnem položaju stran od obraza, z drugo roko pa odtrgajte konico, tako da jo prepognete in zavijte nazaj.
With one hand, hold the Rilonacept Regeneron powder vial on a firm surface.
Z eno roko držite vialo s praškom zdravila Rilonacept Regeneron na trdni podlagi.
With one hand, hold the tip of your penis with your fingers.
S prsti ene roke držite konico penisa.
With one hand, pinch a fold of loose skin.
Z eno roko stisnite kožo v gubo.
With one quick, short motion, push needle all the way into skin
S hitrim, kratkim gibom iglo v celoti zabodite v kožo.
With one quick, short motion, push needle all the way into skin.
S hitrim, kratkim gibom iglo v celoti zabodite v kožo.
With one quick, short motion, push the needle all the way into the skin.
S hitrim in kratkim gibom iglo do konca potisnite v kožo.
with or
ali brez
with or
dasabuvirje
with or at high risk of complete AV block (a type of heart rhythm disorder);
ki imajo ali pri katerih obstaja veliko tveganje za kompletni AV-blok (vrsto motnje srčnega ritma);
with or without
ali brez
with or without cirrhosis, who are not co-infected with HIV
s cirozo ali brez ciroze, ki niso okuženi tudi s HIV
with or without cirrhosis, with or without HIV co-infection
s cirozo ali brez ciroze ter s sočasno okužbo s HIV ali brez nje
with or without dasabuvir
dasabuvirja
with or without dasabuvir .
z ali brez dasabuvirja.
with or without dasabuvir.
ali brez dasabuvirja je
with or without dasabuvir.
dasabuvirjem ali brez
with or without prolongation of the dosing
ali brez podaljšanje razmika med odmerki
With other alpha-blockers a time separation of dose should be considered when vardenafil is prescribed concomitantly (see section 4.5).
Pri sočasnem zdravljenju z vardenafilom in drugimi zaviralci adrenergičnih receptorjev alfa je potreben med zaužitjem enega in drugega zdravila časovni presledek (glejte poglavje 4.5).
with other antiepileptic medicines (add-on therapy) to treat:
kot dopolnilo drugim protiepileptičnim zdravilom za zdravljenje:
with other corticosteroids
istemski učinki kortikosteroidov,
With other human immunoglobulin preparations the following additional symptoms have been reported:
Pri uporabi drugih pripravkov s humanimi imunoglobulini so poročali o naslednjih dodatnih simptomih:
With Parkinson’s disease, there is a loss of cells that produce dopamine in the brain.
Pri Parkinsonovi bolezni nastopi izguba celic, ki v določenih možganskih področjih tvorijo dopamin.
with pre-existing coagulopathies; on coumarin derivates and at an INR above 3.5; using anticoagulants who receive a dose of 16 mg/kg sugammadex.
ki že imajo koagulopatijo; ki jemljejo kumarinske derivate in imajo pri tem vrednost INR nad 3,5; ki jemljejo antikoagulante in prejmejo sugamadeks v odmerku 16 mg/kg.
with pre-existing hypercalcemia and other disturbances in the phosphocalcic metabolism with metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism and Paget’s disease of the bone)
predhodno obstoječo hiperkalciemijo in drugimi motnjami fosfokalcijeve presnove s presnovnimi boleznimi kosti razen osteoporoze (vključno s hiperparatiroidizmom in
with PREZISTA co-administered
PREZISTA skupaj z majhnim
with PREZISTA co-administered with low
midazolama in zdravila PREZISTA skupaj
With primary
(n = 111)
With primary
S primarno profilakso z G-CSF
With prior treatment of at least Imatinib
pospešena faza, predhodno zdravljenje vsaj z imatinibom
With protocol-specified management guidelines, resolution occurred in most cases (87%), with a median time from onset to resolution of 5 weeks (range 0.6 to 29 weeks).
Po ukrepanju v skladu s smernicami, določenimi s protokolom, se je stanje pri večini bolnikov (87 %) izboljšalo, mediani čas od pojava do izboljšanja pa je bil 5 tednov (razpon 0,6 do 29 tednov).
With protocol-specified management guidelines, time to resolution ranged from 0.7 to 2 weeks.
Po ukrepanju v skladu s smernicami, določenimi s protokolom, je do izboljšanja prišlo v 0,7 do 2 tednih.
With RBV Without RBV
Z RBV Brez RBV
With regard to centrally-acting antihypertensives, beta-blockers may exacerbate the rebound hypertension after clonidine abrupt withdrawal, and propranolol should be stopped several days before discontinuing clonidine.
Kar zadeva centralno delujoče antihipertenzive, antagonisti adrenergičnih receptorjev beta poslabšajo povratno hipertenzijo po nenadni prekinitvi jemanja klonidina, propranolol je zato treba prenehati jemati nekaj dni pred prenehanjem jemanja klonidina.
With regard to GIST, the Committee noted that the outlook is poor for patients whose disease gets worse despite treatment with imatinib and sunitinib.
V zvezi z gastrointestinalnim stromalnim tumorjem je opozoril, da so izgledi slabi pri bolnikih, katerih bolezen se poslabša kljub zdravljenju z imatinibom in sunitinibom.
With regard to its risks, around half of the patients taking Zelboraf experienced a severe side effect and about one fifth developed cutaneous squamous cell carcinoma.
Glede z njim povezanih tveganj so se pri približno polovici bolnikov, ki so jemali zdravilo Zelboraf, pojavili resni neželeni učinki, približno pri eni petini pa se je razvil ploščatocelični karcinom kože.
With regard to other AEs and considering all double-blind, placebo-controlled studies in patients diagnosed with diseases other than PNH (N=526 patients with Soliris; N=221 patients with placebo), AEs reported with Soliris at a frequency of 2% or greater than the frequency reported with placebo were: upper respiratory tract infection, rash, and injury.
V zvezi z drugimi neželenimi dogodki in ob upoštevanju vseh dvojno slepih, s placebom kontroliranih študij so pri bolnikih, pri katerih so bile diagnosticirane druge bolezni, ne PNH (n = 526 bolnikov, zdravljenih z zdravilom Soliris; n = 221 bolnikov, zdravljenih s placebom), pri jemanju zdravila Soliris poročali o naslednjih neželenih dogodkih s pogostostjo, večjo za 2 % ali več kot pri placebu: okužbe zgornjih dihal, izpuščaji in poškodbe.
With regard to safety, the Committee noted an acceptable safety profile .
Z vidika varnosti je odbor ugotovil, da je varnostni profil sprejemljiv.
With regard to safety, the Committee noted an acceptable safety profile.
V zvezi z varnostjo je odbor ugotovil, da je varnostni profil sprejemljiv.
With regard to safety, the side effects reported in the Sirturo group in the main study were not markedly different from those in the placebo group, though there were higher levels of liver enzymes and some reports of alterations in the heart’s electrical activity (known as prolonged QT interval).
Kar zadeva varnost, se neželeni učinki, o katerih so v glavni študiji poročali v skupini bolnikov, ki so jemali zdravilo Sirturo, niso bistveno razlikovali od tistih, ki so jih opazili v skupini, zdravljeni s placebom, vendar pa so zabeležili višje ravni jetrnih encimov in nekaj poročil o spremembah v električni aktivnosti srca (t. i. podaljšanju intervala QT).
With regard to safety, the side effects reported in the studies did not raise any major concerns.
Neželeni učinki, o katerih so poročali v študijah, niso vzbudili večjih pomislekov glede varnosti.
With regard to safety, the vaccinia virus in Imvanex cannot replicate in human cells and hence is less likely to cause side effects than previous smallpox vaccines.
V zvezi z varnostjo je bilo ugotovljeno, da se virus vakcinija v cepivu Imvanex ne more podvajati v človeških celicah, zato je manj možnosti za neželene učinke kot pri prejšnjih cepivih proti črnim kozam.
With regard to secondary endpoints, no significant difference was detected in terms of incidence of laboratory TLS (8.1% and 9.2% in ADENURIC and allopurinol arm, respectively; relative risk: 0.875 [95% confidence interval: 0.4408 ; 1.7369]; p=0.8488) nor of clinical TLS (1.7% and 1.2% in ADENURIC and allopurinol arm, respectively; relative risk: 0.994 [95% confidence interval: 0.9691 ; 1.0199]; p=1.0000).
Pri sekundarnih opazovanih dogodkih ni bilo izmerjenih pomembnih razlik glede incidence laboratorijske TLS (8,1 % pri zdravilu ADENURIC oziroma 9,2 % pri alopurinolu; relativno tveganje: 0,875 [95% interval zaupanja: 0,4408; 1,7369]; p=0,8488) in klinične TLS (1,7% pri zdravilu ADENURIC oziroma 1,2 % pri alopurinolu; relativno tveganje: 0,994 [95% interval zaupanja: 0,9691; 1,0199]; p=1,0000).
With regard to the acute pain (pain between 0-30 days) there was no statistically significant difference between the vaccine group and the placebo group.
Za akutno bolečino (bolečina 0-30 dni) ni bilo statistično pomembne razlike med skupino, ki je prejela cepivo, in skupino na placebu.